Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Omeros Corporation - Common Stock (NQ:OMER)

14.38 -0.38 (-2.57%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,377,107
Open 14.77
Bid (Size) 14.77 (200)
Ask (Size) 14.80 (400)
Prev. Close 14.76
Today's Range 13.78 - 14.86
52wk Range 2.950 - 17.65
Shares Outstanding 62,855,824
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Omeros Corp (NASDAQ:OMER) Swings to Profit on YARTEMLEA Launch, Topping EPS Forecasts ↗
Via Chartmill
News headline image
Omeros Corporation Reports First Quarter 2026 Financial Results
From Omeros Corporation
Via Business Wire

Performance

YTD
-12.2%
-12.2%
1 Month
+26.4%
+26.4%
3 Month
+28.0%
+28.0%
6 Month
+108.7%
+108.7%
1 Year
+224.6%
+224.6%

More News

Read More
News headline image
Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026
From Omeros Corporation
Via Business Wire
News headline image
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)
From Omeros Corporation
Via Business Wire
Omeros Corp (NASDAQ:OMER) Reports Q4 2025 Earnings Boosted by Major Asset Sale, Launches First Commercial Product ↗
Via Chartmill
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026
From Omeros Corporation
Via Business Wire
News headline image
Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment
From Omeros Corporation
Via Business Wire
News headline image
Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program
From Omeros Corporation
Via Business Wire
News headline image
Omeros Announces First Commercial Sales of YARTEMLEA®
From Omeros Corporation
Via Business Wire
News headline image
Nasdaq, S&P 500 Futures Dip As Investors Brace For Jobs Data, Tariff Ruling: Why NVDA, MSFT, AAPL, APLD, NIO Are On Traders' Radar Today ↗
Via Stocktwits
Topics ETFs Government Stocks
News headline image
Why Did Omeros Stock Jump 5% In After-Hours Trading Today? ↗
Via Stocktwits
News headline image
Omeros Announces New Date for YARTEMLEA® Approval Conference Call
From Omeros Corporation
Via Business Wire
News headline image
Why Omeros Stock Skyrocketed Today ↗
Via The Motley Fool
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
News headline image
Retail’s Christmas Eve Watchlist: Omeros, Nike, Citi, Dynavax And Agios Spark Most Market Chatter ↗
Via Stocktwits
Topics ETFs Economy Stocks
News headline image
Top movers in Wednesday's session ↗
Via Chartmill
News headline image
Which stocks are gapping on Wednesday? ↗
Via Chartmill
News headline image
Omeros Stock Jumps Premarket After FDA Approves First Drug For Rare Transplant Complication — Retail Sees Big Upside ↗
Via Stocktwits
News headline image
FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA
From Omeros Corporation
Via Business Wire
News headline image
Omeros Stock Garners High Retail Attention Ahead Of FDA Verdict For Life-Saving Drug ↗
Via Stocktwits
News headline image
Omeros Corp Sells Immune-System Drug To Novo Nordisk In $2.1B Deal — Retail Shifts Focus To Narsoplimab FDA Call ↗
Via Stocktwits
Topics Intellectual Property
News headline image
Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)
From Omeros Corporation
Via Business Wire

Frequently Asked Questions

Is Omeros Corporation - Common Stock publicly traded?
Yes, Omeros Corporation - Common Stock is publicly traded.
What exchange does Omeros Corporation - Common Stock trade on?
Omeros Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Omeros Corporation - Common Stock?
The ticker symbol for Omeros Corporation - Common Stock is OMER on the Nasdaq Stock Market
What is the current price of Omeros Corporation - Common Stock?
The current price of Omeros Corporation - Common Stock is 14.38
When was Omeros Corporation - Common Stock last traded?
The last trade of Omeros Corporation - Common Stock was at 05/13/26 04:00 PM ET
What is the market capitalization of Omeros Corporation - Common Stock?
The market capitalization of Omeros Corporation - Common Stock is 903.87M
How many shares of Omeros Corporation - Common Stock are outstanding?
Omeros Corporation - Common Stock has 904M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.